培美曲塞联合奥沙利铂化疗对晚期非小细胞肺癌的临床疗效  

Clinical Efficacy of Pemetrexed Combined with Oxaliplatin Chemotherapy for Advanced Non-small Cell Lung Cancer(NSCLC)

作　　者：杨华[1] 蔡卓倩[1] 

机构地区：[1]南京医科大学附属无锡市人民医院,214023

出　　处：《实用癌症杂志》2016年第12期2004-2007,共4页The Practical Journal of Cancer

摘　　要：目的探讨培美曲塞联合奥沙利铂化疗对晚期非小细胞肺癌的临床疗效。方法选取100例晚期非小细胞肺癌的患者,按照随机数表法将100例患者分为对照组与观察组。对照组采用常规化疗方法,即应用吉西他滨联合奥沙利铂化疗。观察组采用培美曲塞联合奥沙利铂化疗。观察比较两组患者临床疗效,生活质量,血清糖类抗原(CA)125及癌胚抗原(CEA)水平变化,不良反应。结果观察组临床有效率为40.0%,对照组为34.0%,两组有效率比较无统计学意义(P>0.05),观察组临床控制率为80.0%,对照组临床控制率为74.0%,无统计学意义(P>0.05)。观察组治疗后体质量为(71.9±5.1)kg,明显高于对照组患者的(66.9±3.1)kg,差异明显,具有统计学意义(P<0.05)。观察组在治疗后卡氏评分为(86.4±5.7)分,明显高于对照组患者的(75.4±4.7)分,差异明显,具有统计学意义(P<0.05)。观察组在治疗后血清CEA含量为(10.2±6.1)μg·L-1,明显低于对照组患者的(19.3±5.9)μg·L-1,差异明显,具有统计学意义(P<0.05)。观察组在治疗后CA125含量为(38.8±3.2)U·m L-1,明显低于对照组患者的(49.3±2.1)U·m L-1,差异明显,具有统计学意义(P<0.05)。两组患者不良反应比较,未见统计学差异(P>0.05)。结论培美曲塞联合奥沙利铂化疗对患者生活质量的恢复具有显著作用。Objective To investigate the clinical efficacy of pemetrexed combined with oxaliplatin chemotherapy for ad- vanced non-small cell lung cancer（NSCLC）. Methods 100 patients with advanced NSCLC were divided into the control group and the observation group. The control group was treated with conventional chemotherapy of gemcitabine combined with oxaliplatin chemotherapy. The observation group was treated with pemetrexed combined with oxaliplatin chemotherapy. Clinical efficacy, qual- ity of life, serum carbohydrate antigen（CA） 125 and（CEA） levels were observed and compared between the 2 groups. Results Clinical effective rate of the observation group was 40.0% ,higher than that of the control group ,34.0% ,but there had no statisti- cal difference（P 〉 0.05 ）. Control rate of the observation group was 80%, which was higher than that of the control group, 74.0%, but there had no statistical difference （P 〉 0.05 ）. The body weight of the observation group after treatment was （71.9±5.1 ） kg, which was significantly higher than that of the control group, （66.9±3. 1 ） kg, there had statistical difference （P 〈0. 05 ）. In the observation group, after treatment, the card＇s score was （ 86.4±5.7）, which was significantly higher than that of the control group, （75.4±4.7）, the difference was significant, with statistical significance（ P 〈 0.05 ）. Serum CEA levels after treatment of the observation group was（ 10.2±6.1 ）μg/L,which was significantly lower than that of the control group, （ 19.3±5.9） μg/L, there had statistical difference （P 〈 0.05 ）. The content of CA125 in the observation group after treatment was （38.8±3.2） U/mL, which was significantly lower than that of the control group, （49.3±2.1 ） U/mL, the difference was significant, with sta- tistical significance（ P 〈 0.05 ）. Toxicity of the 2 groups had no statistically significant difference（ P 〉 0.05 ）, pemetrexed combined with oxaliplatin chemotherapy for patients had small

关 键 词：培美曲塞 奥沙利铂 晚期非小细胞肺癌 化疗 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]